Key Takeaways
- Morgan Stanley shifted ARM rating from Overweight to Equal-Weight
- Price objective reduced to $150 from previous $185 target
- Concerns include weakening end markets and memory supply bottlenecks
- Potential friction with licensees as Arm enters chip production directly
- Competing analysts from Mizuho, UBS, and Needham maintain optimistic outlooks with elevated targets
Shares of Arm Holdings declined 3.7% during premarket hours on Tuesday following a rating cut from Morgan Stanley, which pointed to immediate challenges despite recognizing the company’s long-term potential in chip manufacturing.
Arm Holdings plc American Depositary Shares, ARM
Lee Simpson, the covering analyst, adjusted his stance on ARM to Equal-Weight from Overweight while lowering his price objective to $150, down from $185. This revision followed closely on the heels of Arm’s announcement of its new artificial general intelligence-focused CPU, with Meta and OpenAI emerging as initial customers.
Simpson recognized the strategic merit of the company’s direction. He noted that the specialized CPU designed for agentic AI applications demonstrates the processor’s continued relevance in modern computing. He also commended the firm’s ability to attract top-tier talent and execute rapid design cycles.
However, Simpson also highlighted significant obstacles. He emphasized that scaling the business model will require considerable time, and current market excitement may need recalibration.
Weakening Market Conditions Pose Challenge
Demand uncertainty represents a primary concern in the analysis. Simpson suggested that investor attention will likely return to Arm’s conservative guidance amid challenging market conditions.
Weakness across end markets, coupled with constrained DRAM availability, could create headwinds for growth in the 2027 fiscal year, according to the analyst. This represents a significant near-term challenge for a company trading at premium multiples.
Profitability pressure adds another layer of complexity. According to Morgan Stanley, elevated research and development spending is occurring well before substantial chip-related revenue materializes.
Potential Customer Tension
Among the most notable concerns outlined in the research note was the possibility of channel conflict. With Arm’s entry into silicon production, the company now finds itself in potential competition with organizations that license its intellectual property.
Simpson warned that this development could trigger customer resistance, urging investors not to underestimate this dynamic.
The situation is nuanced. Arm established its market position as an impartial provider of processor designs. Expanding into direct chip production fundamentally alters this relationship.
Divergent Wall Street Views
Morgan Stanley’s cautious perspective isn’t universally shared across the investment community. Mizuho maintains a $230 price target for ARM, emphasizing growth opportunities in AI-driven data centers. UBS holds a $175 target with a Buy recommendation. Needham recently upgraded the stock to Buy with a $200 objective. Barclays similarly rates it Overweight with a $200 valuation.
At the time of the downgrade, ARM stock was changing hands at $148.77, giving the company a market capitalization of approximately $158 billion. InvestingPro analysis suggested the shares were trading above their Fair Value calculation.
